Skip to content

Metabolic Support With Perhexiline to Protect Myocardium Undergoing Coronary Artery Surgery

Metabolic Support With Perhexiline to Protect Myocardium Undergoing Coronary Artery Surgery

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00845364
Acronym
CASPER
Enrollment
290
Registered
2009-02-18
Start date
2007-02-28
Completion date
2010-04-30
Last updated
2010-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Output, Low, Myocardial Reperfusion Injury

Keywords

Perhexiline, Coronary artery bypass, Myocardial reperfusion injury, Cardiac output, low, Troponin

Brief summary

Open-heart surgery causes injury of the heart muscle. Although this is usually mild, temporary and reversible, if it is severe it can endanger life and require additional high cost care. During surgery, techniques are used to protect the heart from injury, but these remain imperfect. This study assesses the effect of facilitating sugar metabolism (a more efficient fuel) by the heart muscle using the drug Perhexiline given before the operation. This treatment has a sound experimental basis for improving outcome. If this improvement is confirmed surgical results could be improved. The investigators will be studying heart function, heart muscle energy stores and chemicals which quantify the amount of heart muscle injury. The investigators' hypothesis is that Perhexiline will improve the protection of the heart by decreasing damage that may occur during heart surgery.

Interventions

Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.

Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.

Sponsors

University of Birmingham
CollaboratorOTHER
Brighton and Sussex University Hospitals NHS Trust
CollaboratorOTHER
British Heart Foundation
CollaboratorOTHER
University Hospital Birmingham
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult * First-time * Isolated coronary artery bypass surgery

Exclusion criteria

* Diabetes Mellitus * Renal impairment with Creatinine greater than or equal to 200micromol/L * Atrial fibrillation * Amiodarone therapy, recent (in last month) or current * Hepatic impairment, significant preoperative * Peripheral neuropathy * Pregnancy or breast-feeding * Emergency surgery or required on clinical grounds within 5 days of referral

Design outcomes

Primary

MeasureTime frame
Incidence of Low Cardiac Output Syndrome6 hours post-removal of aortic X-clamp

Secondary

MeasureTime frame
Increase in Cardiac index of greater than or equal to 0.3 L/min/m26 hours post-removal of aortic X-clamp
Incidence of inotropes use according to protocol6 and 12 hours post-removal of aortic X-clamp
Peak and total release of Troponin6, 12 and 24 hours post-release of aortic X-clamp

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026